Burlingame, April 13, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global human platelet lysate market is estimated to be valued at US$ 53.0 million in 2023 and is expected to exhibit a CAGR of 4.54% during the forecast period (2023-2030).
Analyst Views:
Major players operating in the market are focusing on adopting strategies such as partnership, which is expected to drive the market growth over the forecast period. For instance, on October 3, 2022, Sysmex, a healthcare company announced partnership with JCR Pharmaceuticals, a pharmaceutical company. This companies formed partnership for carrying out research and development, manufacture and sales of cell-based regenerative medicine products including hematopoietic stem cells and other stem cells such as hematopoietic stem cells, mesenchymal stem cells, and iPS cells.
Request Sample copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/5613
Key Trends and Analysis of the Global Human Platelet Lysate Market:
Increasing adoption of inorganic growth strategies such as acquisition
Major players operating in the market are focusing on adopting strategies such as acquisition, which is expected to drive the market growth over the forecast period. For instance, on April 4, 2022, Metcela, a biotechnology company announced the acquisition of regenerative medicine co., ltd., a biotechnology company, to further accelerate the research and development (R&D) activities in cell therapy.
Driver:
Increase in the research and development of human platelet lysate for treatment of traumatic brain injury
Increase in the research and development of human platelet lysate for treatment of traumatic brain injury is expected to drive the growth of the market over the forecast period. For instance, data published in June 2021, stated that the human platelet lysate is a reliable and effective therapeutic source of neurorestorative factors. Brain administration of platelet lysate is a therapeutical strategy that deserves serious and urgent consideration for universal brain trauma treatment.
Human Platelet Lysate Market Report Coverage
| Report Coverage | Details | |||
| Base Year: | 2022 | Market Size in 2023: | US$ 53.0 Mn | |
| Historical Data for: | 2017 to 2021 | Forecast Period: | 2023 to 2030 | |
| Forecast Period 2023 to 2030 CAGR: | 4.54% | 2030 Value Projection: | US$ 72.3 Mn | |
| Geographies covered: |
| |||
| Segments covered: |
| |||
| Companies covered: | STEMCELL Technologies Inc., Merck KGaA, Mill Creek Life Sciences, Merck & Co., Inc, AventaCell BioMedical, Compass Biomedical, Inc, Macopharma SA, Trinova Biochem GmbH, PL BioScience GmbH, Cook Regentec, Life Science Group Ltd., BBI Solutions, Regenexx, Thermo Fisher Scientific. | |||
| Growth Drivers: |
| |||
| Restraints & Challenges: |
| |||
Restraint:
Risk of transmission of infectious communicable diseases
Increase in the transmission of infectious communicable diseases is expected to hamper the growth of the market over the forecast period. There is possibility of transfusion-transmitted infections, most specifically virus transmissions when using human platelet lysates. As it is blood derived product there is risks of transmission of blood-borne pathogens to patients.
Request Customization of this Report @ https://www.coherentmarketinsights.com/insight/request-customization/5613
Market Trends:
Increasing adoption of inorganic growth strategies such as merger
Increasing adoption of inorganic growth strategies such as collaboration by the key players in the market is expected to drive the growth of the market over the forecast period. For instance, on February 2, 2022, Calidi Bio therapeutics, a clinical-stage biopharmaceutical company and Edoc Acquisition Corp, a blank check company announced merger of the companies to create a publicly listed, clinical-stage biotechnology company utilizing stem cell-based platforms to revolutionize oncolytic virotherapies.
Increasing adoption of inorganic growth strategies such as collaboration
Increasing adoption of inorganic growth strategies such as collaboration by the key players in the market is expected to drive the growth of the market over the forecast period. For instance, on November 2020, Novartis, a pharmaceutical company announced that it entered into a collaboration agreement with Mesoblast, a regenerative medicine company. This collaboration was done to develop commercialize and manufacture remestemcel-L for the treatment of acute respiratory distress syndrome (ARDS), including that associated with COVID-19. As the potential first ARDS therapy, remestemcel-L will use mesenchymal stromal cells (MSCs), a cell-based platform technology, to treat this deadly condition and improve outcomes.
Global Human Platelet Lysate Market Cross Sectional Analysis:
In application segment, clinical use segment is dominant in Europe region due to increasing prevalence of chronic diseases such as osteoarthritis, Parkinson’s diseases, and others. For instance, according to data published in January 2020, on Parkinsons.org.uk, stated that in the U.K., there were approximately 145,000 people living with the Parkinson’s diseases in 2020.
Key Developments:
In August 17, 2022, AGC Biologics, a global CDMO providing development and manufacturing services for protein-based biologics and advanced therapies, announced the partnership with RoosterBio Inc, which is a supplier of human mesenchymal stem/stromal cells (hMSCs). The partnership, creates an end-to-end solution for the development and production of hMSCs and exosome therapeutics using RoosterBio Inc.’s cell and media products and process development services together with AGC Biologics cell and gene therapy manufacturing capabilities.
In January 2021, Sartorius, an international pharmaceutical and laboratory equipment supplier, announced partnership with RoosterBio, which is a supplier of human mesenchymal stem/stromal cells (hMSCs). This partnership aims to advance the scale-up of hMSC manufacturing for regenerative medicine by leveraging the solutions of both companies to significantly reduce process development efforts, industrialize the supply chain and accelerate the development and commercialization of groundbreaking cell-based regenerative cures.
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/5613
Key Market Takeaways:
The global human platelet lysate market is expected to exhibit a CAGR of 4.54% during the forecast period due to increase in the adoption of strategies like acquisition. For instance, in September 2021, Sanofi, a pharmaceutical company, announced the acquisition of Kadmon, a biopharmaceutical company. The acquisition will help the company to expand the company’s expertise in stem cell transplant.
Among application, research use segment is expected to hold a dominant position over the forecast period, owing to increasing in the funding by the governments in research and development activities. For instance, Indian Council of Medical Research (ICMR) released US$ 413,937 in 2021 for stem cell research.
On the basis of type, heparin-free human platelet lysate segment is expected to hold a dominant position over the forecast period, owing to increasing in the adoption of heparin free human platelet lysate. For instance, according to data published in May 2020, on Elsevier, stated that the use of heparin-free materials to mitigate the risk of immune reaction to animal-derived additives i.e. fetal bovine serum (FBS). For this human platelet lysate (hPL) has been accepted as a heparin-free alternative for stem cell expansion.
Competitive Landscape:
Key players operating in the global human platelet lysate market include STEMCELL Technologies Inc., Merck KGaA, Mill Creek Life Sciences, Merck & Co., Inc, AventaCell BioMedical, Compass Biomedical, Inc, Macopharma SA, Trinova Biochem GmbH, PL BioScience GmbH, Cook Regentec, Life Science Group Ltd., BBI Solutions, Regenexx, Thermo Fisher Scientific.
Market Segmentation:
- Global Human Platelet Lysate Market, By Type:
- Heparin - Based Human Platelet Lysate
- Heparin - Free Human Platelet Lysate
- Global Human Platelet Lysate Market, By Application:
- Clinical Use
- Research Use
- Global Human Platelet Lysate Market, By End User:
- Biopharmaceutical Companies
- Contract Research Organizations
- Others
- Global Human Platelet Lysate Market, By Region:
- North America
- By Country
- U.S.
- Canada
- By Country
- Latin America
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Country
- Europe
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- By Country
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- By Country
- Middle East
- By Country
- GCC
- Israel
- Rest of Middle East
- By Country
- Africa
- By Region/Country
- South Africa
- Central Africa
- North Africa
- By Region/Country
- North America
Related Market Intelligence Reports:
Monoclonal Antibody Therapeutics Market, By Source (Human, Chimeric, Murine, and Humanized), by Application (Cancer, Autoimmune Disease, Hematological Disease, Infectious Disease, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2023 – 2030
Human Insulin Drug Market, By Product Type (Human Insulin, Basal Insulin, Bolus Insulin, Insulin Combinations, and Biosimilar Insulins) and By Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America) - Size, Share, Outlook, and Opportunity Analysis, 2022 – 2028
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
